Web of Pharma · QbD · Process Validation · GMP Manufacturing
Critical Process Parameters and Critical Quality Attributes
A practical guide to identifying CQAs and CPPs, linking them through risk assessment, building a control strategy, and monitoring them through PPQ and CPV.
answer
A Critical Quality Attribute (CQA) is a physical, chemical, biological, or microbiological property that must remain within an appropriate limit, range, or distribution to assure product quality. A Critical Process Parameter (CPP) is a process parameter whose variability affects a CQA and therefore must be monitored or controlled. CQAs describe the quality outcome; CPPs describe process inputs or conditions that can influence it.
Pharmaceutical quality is created by the interaction of formulation, materials, equipment, process conditions, people, environment, and measurement systems. Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) provide a practical language for describing those interactions and deciding what must be controlled.
A CQA is not simply every test performed on a finished product. It is an attribute whose variability can affect safety, efficacy, identity, strength, purity, performance, or stability. A CPP is not every number recorded on a batch sheet. It is a parameter whose variation has a meaningful impact on a CQA and therefore requires appropriate monitoring or control.
This article explains how CQAs and CPPs are identified, how Quality by Design (QbD) and ICH risk principles support the analysis, how to build a control strategy, and how to connect the result to Process Validation in Pharmaceuticals and cGMP.
What Is a Critical Quality Attribute?
A Critical Quality Attribute is a measurable physical, chemical, biological, or microbiological property or characteristic that should remain within an appropriate limit, range, or distribution to assure the desired product quality. The attribute may be measured in a starting material, in-process material, intermediate, drug substance, or finished drug product when its control is necessary for the intended quality outcome.
Physical CQAs
Particle size, polymorphic form, bulk density, tablet hardness, thickness, friability, viscosity, appearance, fill volume, or container-closure performance.
Chemical CQAs
Identity, assay, impurities, degradation products, residual solvents, elemental impurities, pH, preservative content, or potency.
Biological CQAs
Biological activity, binding, potency, aggregation, glycosylation, or another product-specific attribute linked to therapeutic function.
Microbiological CQAs
Sterility, microbial limits, endotoxin, bioburden, objectionable organisms, or microbial-control attributes relevant to the dosage form.
Performance CQAs
Dissolution, disintegration, drug release, delivered dose, dose uniformity, reconstitution time, or device delivery performance.
Stability CQAs
Attributes that must remain acceptable during storage, such as assay, impurities, dissolution, moisture, appearance, or microbiological quality.
What Is a Critical Process Parameter?
A Critical Process Parameter is a process parameter whose variability has an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality. A CPP may be a setpoint, range, rate, endpoint, environmental condition, equipment condition, or time-related factor.
| Process area | Possible CPPs | CQAs that may be affected |
|---|---|---|
| Dispensing and charging | Weight accuracy, order of addition, charge rate, material temperature, hold time. | Assay, blend composition, content uniformity, impurity profile. |
| Blending | Blend time, speed, fill level, intensifier use, sequence, humidity. | Blend uniformity, segregation, dissolution, content uniformity. |
| Wet granulation | Binder addition rate, granulation time, impeller speed, chopper speed, endpoint torque. | Granule moisture, particle size, flow, compressibility, dissolution. |
| Drying | Inlet temperature, airflow, product temperature, endpoint moisture, load, drying time. | Moisture, degradation, flow, compressibility, stability. |
| Compression | Compression force, pre-compression, turret speed, feeder speed, dwell time, ejection force. | Weight, hardness, friability, disintegration, dissolution, defects. |
| Coating | Spray rate, atomization pressure, inlet/outlet temperature, pan speed, airflow, solids concentration. | Weight gain, appearance, film integrity, moisture, dissolution. |
| Liquid manufacturing | Mixing speed, temperature, addition rate, homogenization pressure, filtration rate, hold time. | Assay, pH, viscosity, particle size, microbial quality, uniformity. |
| Sterile processing | Sterilization time and temperature, pressure, filter parameters, filling speed, exposure, environmental conditions. | Sterility, endotoxin, potency, particulate matter, container-closure integrity. |
Not every recorded parameter is a CPP. A parameter becomes critical when scientific or statistical evidence shows that its variability can affect a CQA, or when the risk assessment cannot reasonably exclude that impact.
CQA, CPP, CMA, KPP, and KQA: How the Terms Fit
Pharmaceutical development uses several related terms. Their meaning should be defined in the product and process knowledge management system so that development, validation, manufacturing, and regulatory teams use them consistently.
| Term | Meaning | Practical role |
|---|---|---|
| CQA | Quality attribute that must be controlled within an appropriate limit, range, or distribution to assure desired product quality. | Defines the quality outcome to protect. |
| CPP | Process parameter whose variability affects a CQA and therefore should be monitored or controlled. | Defines a process condition that needs control. |
| CMA | Critical material attribute whose variability can affect a CQA or process performance. | Defines an input property such as particle size, moisture, grade, or concentration. |
| KPP | Key process parameter used to operate or understand the process; it may be important without meeting the CPP definition. | Supports monitoring and process knowledge. |
| KQA | Key quality attribute that is useful for development or monitoring but may not be critical to patient risk. | Supports trending, characterization, or optimization. |
| Control strategy | Planned set of controls derived from current product and process understanding. | Connects materials, equipment, CPPs, CQAs, tests, monitoring, and responses. |
How CQAs and CPPs Are Identified
Identification is iterative. Development knowledge, prior product experience, laboratory studies, scale-up, engineering runs, process characterization, risk assessment, and commercial data can all refine the list. The final selection should be traceable to evidence rather than copied from a generic template.
Define the QTPP
Describe intended use, dosage form, route, strength, release, stability, container, and patient-relevant quality objectives.
List potential CQAs
Identify physical, chemical, biological, microbiological, performance, and stability attributes that may affect product quality.
Rank quality risk
Assess severity of harm and the scientific relationship between each attribute and safety, efficacy, identity, strength, purity, or performance.
Map the process
Break manufacturing into unit operations, inputs, equipment, outputs, hold points, controls, and likely sources of variation.
Identify CMAs and parameters
Evaluate material attributes and process parameters that could change a CQA or the process’s ability to meet it.
Use experiments
Apply DOE, challenge studies, scale-up data, PAT, modeling, and targeted experiments to understand cause-and-effect relationships.
Confirm criticality
Use risk tools and evidence to distinguish CPPs from non-critical or key parameters and document uncertainty.
Maintain the map
Update CQAs, CPPs, and controls when new data, changes, deviations, CPV trends, or regulatory knowledge become available.
Use SOP controls for approval, versioning, training, and change management of the CQA/CPP map.
Risk Assessment for CPP and CQA Criticality
Quality risk management connects product impact with process uncertainty. The assessment should be formal enough for the risk and should use current scientific knowledge, data, and subject-matter expertise.
Severity
How serious could the patient or product consequence be if the attribute is outside its required state?
Occurrence
How likely is the attribute or parameter to vary beyond the acceptable range under the proposed process?
Detectability
How likely is the failure to be detected before release or before it affects the next process step?
Knowledge strength
Is the relationship supported by development data, prior knowledge, modeling, or only expert assumption?
Control strength
Can the risk be controlled by material specifications, process limits, alarms, PAT, in-process tests, or final testing?
Uncertainty
What is not known about scale, equipment, material variability, interactions, or the measurement method?
ICH risk principles distinguish the criticality of an attribute from the risk controls applied to it. A CQA’s potential quality impact remains important even when controls reduce the probability of failure. A process parameter’s criticality can change as understanding, detectability, and control effectiveness improve.
Document the assessment using a suitable method such as FMEA, fault-tree analysis, HACCP, cause-and-effect mapping, or a structured risk-ranking approach aligned with ICH Quality Guidelines.
From CQA and CPP Mapping to a Control Strategy
A control strategy is the planned set of controls derived from current product and process understanding. It should protect CQAs through a combination of material controls, equipment controls, process limits, monitoring, in-process tests, release tests, and lifecycle review.
| Control layer | Examples | How it protects a CQA |
|---|---|---|
| Material controls | API identity, particle size, moisture, polymorph, excipient grade, microbiological quality. | Reduces input variability before processing begins. |
| Equipment and facility | Qualified equipment, temperature control, airflow, pressure cascade, clean status, calibration. | Creates a reproducible environment for the process. |
| Process parameters | CPP setpoints, operating ranges, alarms, interlocks, recipe controls, endpoint limits. | Keeps the process inside a proven operating space. |
| In-process monitoring | PAT, moisture check, torque, pH, viscosity, weight, blend uniformity, visual inspection. | Detects variation early enough to respond. |
| Sampling and testing | Location-based sampling, validated analytical methods, microbiological testing, sterility tests. | Confirms the process and product meet defined quality requirements. |
| Lifecycle monitoring | CPV trends, control charts, deviations, complaints, stability, CAPA, periodic review. | Checks that the validated state remains effective during routine production. |
Design Space and Proven Acceptable Ranges
A design space is the multidimensional combination and interaction of input variables and process parameters demonstrated to provide assurance of quality. It can include material attributes, CPPs, and their interactions rather than a list of isolated single-factor limits.
| Concept | Meaning | Practical example |
|---|---|---|
| Setpoint | Intended operating value chosen for routine manufacturing. | Compression force target of 12 kN. |
| Normal operating range | Routine range used by trained operators under approved instructions. | Compression force 10–14 kN. |
| Proven acceptable range | Range demonstrated by evidence to produce acceptable quality under defined conditions. | Binder addition rate 1.0–1.4 kg/min with acceptable granule properties. |
| Design space | Multivariable region in which quality is assured based on development and process knowledge. | Interaction of moisture, impeller speed, binder rate, and granulation endpoint. |
| Alert/action limit | Internal limit used to identify drift or require action before or when quality risk becomes unacceptable. | CPV trend alert for increasing tablet-weight variability. |
A design space is not permission to operate outside approved controls without evaluation. Changes within or outside a design space still require the applicable site and regulatory change-management assessment.
CPP and CQA Examples by Dosage Form
| Dosage form | Example CQAs | Example CPPs | Typical control approach |
|---|---|---|---|
| Immediate-release tablets | Assay, content uniformity, dissolution, hardness, friability, disintegration, impurities. | Blend time, granule moisture, lubrication time, compression force, turret speed, coating temperature. | Material controls, blend sampling, moisture endpoint, compression monitoring, dissolution and CPV trends. |
| Modified-release tablets | Release profile, assay, content uniformity, coating integrity, impurities, stability. | Polymer level, granulation moisture, coating weight gain, spray rate, drying temperature, pan speed. | QbD studies, coating process controls, dissolution profile monitoring, stability and change control. |
| Oral liquids | Assay, pH, viscosity, uniformity, microbial limits, preservative, fill volume. | Mixing speed, temperature, addition sequence, homogenization, filtration, hold time, filling speed. | In-process checks, microbial controls, hold-time validation, fill-volume monitoring, finished-product testing. |
| Sterile injectables | Sterility, endotoxin, particulate matter, assay, fill volume, container-closure integrity. | Sterilization cycle, filter parameters, filling speed, environmental conditions, pressure, hold time. | Contamination-control strategy, qualified utilities, aseptic monitoring, sterilization validation, integrity testing. |
| Capsules | Assay, content uniformity, dissolution, moisture, capsule integrity, weight variation. | Blend time, hopper level, machine speed, dosing settings, environmental humidity, locking force. | Blend uniformity, machine setup controls, weight checks, environmental monitoring, dissolution and CPV. |
| Topical products | Assay, viscosity, pH, particle size, homogeneity, microbial quality, spreadability. | Mixing speed, temperature, homogenization pressure, cooling rate, addition order, deaeration. | Temperature profile, endpoint testing, homogenization controls, microbial testing, packaging checks. |
Monitoring CQAs and CPPs During PPQ and CPV
Process performance qualification demonstrates that a commercial-scale process can reproducibly deliver quality. Continued process verification then checks whether the process remains in a state of control during routine production. The CQA/CPP map should determine what is sampled, how often it is reviewed, and what triggers escalation.
Set the baseline
Use development, scale-up, qualification, and PPQ evidence to define expected ranges and sources of variation.
Choose indicators
Select CQAs, CPPs, material attributes, in-process tests, and quality events that can reveal loss of control.
Define frequency
Set sampling and review frequency according to risk, process knowledge, historical performance, and lifecycle stage.
Trend the data
Use time plots, control charts, capability analysis, batch stratification, and multivariate review when appropriate.
Set escalation rules
Define alert, action, investigation, change-control, and CAPA triggers before the trend is reviewed.
Review context
Connect signals to materials, equipment, operators, environment, maintenance, deviations, complaints, and stability.
Act proportionately
Apply correction, enhanced monitoring, requalification, change control, investigation, or revalidation based on risk.
Update knowledge
Feed confirmed learning back into the CQA/CPP map, control strategy, training, and validation documents.
The FDA process-validation lifecycle recommends continued monitoring and sampling at the level established during process qualification. Use a controlled SOP to define ownership and review timelines.
Measurement, Qualification, and Data Integrity
A CQA or CPP is only useful when it can be measured, controlled, and reviewed reliably. Instruments, equipment, software, methods, sampling tools, and operators should be qualified for their intended use.
URS and design
Define critical functions, ranges, alarms, data, and control needs in the URS and review design intent through DQ.
Installation
Use IQ to confirm identity, location, utilities, instruments, software version, materials, and calibration status.
Operation
Use OQ to challenge operating ranges, alarms, interlocks, controls, calculations, and worst-case functions.
Performance
Use PQ or process-performance evidence to show that the system works with real product, loads, operators, and routine conditions.
Data reliability
Protect original data, audit trails, calculations, metadata, access, backup, and review according to ALCOA+.
Electronic records
Where applicable, review electronic records, signatures, access controls, audit trails, and retention against 21 CFR requirements.
Change Control, Deviations, and CAPA
CQAs and CPPs must remain connected to the quality system after development and validation. A new material supplier, formulation, equipment train, software version, batch size, facility, method, or process range may alter the relationship between a parameter and an attribute.
| Quality event | Question to ask | Possible action |
|---|---|---|
| Process change | Could the change alter a CQA, CPP, CMA, operating range, or control strategy? | Risk assessment, development/engineering study, targeted verification, or revalidation. |
| Deviation or OOS/OOT | Does the result indicate a weak relationship, an unrecognized parameter, or a failed control? | Investigation, product impact assessment, enhanced monitoring, or CAPA. |
| Trend or drift | Is a CQA moving toward a limit or is a CPP leaving its normal operating range? | CPV escalation, root-cause review, process adjustment, or change control. |
| Equipment modification | Could geometry, control logic, surface, scale, heat transfer, or measurement change? | Qualification impact assessment, IQ/OQ/PQ, engineering runs, and process verification. |
| New knowledge | Does new toxicology, stability, impurity, regulatory, or scientific knowledge change criticality? | Update the risk assessment, specifications, control strategy, and validation documents. |
Use CAPA new for the current corrective and preventive action workflow, while retaining the established CAPA procedure where it is the site reference.
Audit-Ready CQA and CPP Documentation
An inspector should be able to trace every critical attribute and parameter from product objective to scientific evidence, risk decision, control, monitoring record, and response.
- Quality Target Product Profile is approved and linked to intended product quality.
- CQA definitions, units, limits, ranges, distributions, and criticality rationale are documented.
- Potential CQAs, CPPs, CMAs, and key parameters are identified for every relevant unit operation.
- Risk assessment links each critical parameter or material attribute to affected CQAs.
- Development, DOE, scale-up, modeling, PAT, and prior knowledge are traceable to the conclusion.
- Design space, proven acceptable ranges, normal operating ranges, alarms, and action limits are distinguished.
- Material, equipment, facility, method, software, and sampling controls are included in the control strategy.
- PPQ and CPV protocols define sampling, testing, frequency, trends, alert/action rules, and responsibilities.
- Qualification, calibration, method validation, data review, audit-trail review, and training records are current.
- Deviations, OOS/OOT, complaints, stability, CAPA, changes, and periodic reviews feed back into the CQA/CPP map.
- All records are attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.
- QA approves the final risk assessment, validation strategy, control strategy, and lifecycle updates.
Key Takeaways
- CQAs describe quality outcomes that must be controlled to protect safety, efficacy, identity, strength, purity, performance, or stability.
- CPPs are process parameters whose variability affects a CQA and therefore require appropriate monitoring or control.
- CMAs, CPPs, CQAs, and the control strategy should be linked through evidence-based risk assessment.
- QbD begins with the quality target product profile and grows through development knowledge, experiments, scale-up, and lifecycle learning.
- A design space is a demonstrated multidimensional operating region, not permission to bypass approved change control.
- PPQ and CPV should monitor the critical variables at a frequency and depth justified by risk and process knowledge.
- Qualification, measurement-system readiness, data integrity, deviations, CAPA, and periodic review are essential parts of the CQA/CPP lifecycle.
Conclusion
Critical Quality Attributes and Critical Process Parameters create the bridge between pharmaceutical development and reliable manufacturing. CQAs define the quality that matters; CPPs identify the process conditions that can influence that quality. When the relationship is supported by science and risk assessment, the organization can build a control strategy that is more predictive than end-product testing alone.
The strongest CQA/CPP program remains active throughout the lifecycle. It is refined by PPQ and CPV data, changed by new knowledge, challenged by deviations and trends, and protected by qualification, data integrity, CAPA, and management review. That discipline turns process validation into a living system for maintaining product quality.
Related Pharmaceutical Quality Guides
Connect CQA and CPP work with the wider WebOfPharma validation and quality-system series:
Frequently Asked Questions
What is a Critical Quality Attribute?
A Critical Quality Attribute is a physical, chemical, biological, or microbiological property or characteristic that should remain within an appropriate limit, range, or distribution to assure the desired product quality.
What is a Critical Process Parameter?
A Critical Process Parameter is a process parameter whose variability affects a Critical Quality Attribute and therefore should be monitored or controlled to ensure the process produces the desired quality.
Are all process parameters critical?
No. A process may have many recorded parameters, but a parameter is critical only when scientific evidence or risk assessment shows that its variability can affect a CQA or when that impact cannot reasonably be excluded.
Can a CQA be an in-process attribute?
Yes. A CQA can apply to a starting material, intermediate, in-process material, drug substance, or finished product when control of that attribute is necessary to assure the intended quality outcome.
How are CQAs and CPPs identified?
They are identified through the quality target product profile, prior knowledge, development studies, risk assessment, process mapping, DOE, scale-up, engineering studies, PAT, and lifecycle manufacturing data.
What is the difference between a CPP and a CMA?
A CPP is a process parameter whose variability can affect a CQA. A Critical Material Attribute is a property of a material input, such as moisture, particle size, grade, or polymorph, that can affect a CQA or process performance.
Does a high-risk CPP always need continuous monitoring?
Not necessarily. The monitoring frequency and method should be proportionate to risk, process knowledge, detectability, variability, and the control strategy. A parameter may be controlled by a validated setpoint, alarm, in-process check, PAT, or periodic verification.
How are CQAs and CPPs used in PPQ?
The CQA/CPP map defines what must be challenged, sampled, tested, and trended during process performance qualification. It also supports acceptance criteria and the transition to continued process verification.
What happens when a CPP trend moves toward a limit?
Review the data and context, confirm measurement quality, assess product impact, and follow the predefined alert/action procedure. The response may include enhanced monitoring, investigation, maintenance, change control, CAPA, or revalidation.
Can CQAs and CPPs change after approval?
Yes. New process knowledge, deviations, CPV trends, formulation or equipment changes, new analytical information, stability results, or regulatory expectations may require the CQA/CPP map and control strategy to be updated through change control.
.webp)
